Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

that variation has the potential to become a blockbuster drug, according to Chief Executive Richard Adcock. But all these grand plans were contingent on one thing: a continuous string of approvals ...

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...

driven by expanding use of existing drugs for new indications and the introduction of expensive blockbuster drugs.[19] The Hatch-Waxman Act effectively created a dual market: one with robust ...

Takeda is internationally well known for discovering and developing several blockbuster drugs, including Prevacid (heartburn), Actos (diabetes), Leuprorelin (various cancers), and Blopress ...

Merck boasts more than six blockbuster drugs in its portfolio, with Keytruda being the key top-line driver. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in ...

The maker of blockbuster drugs Wegovy and Ozempic cited ongoing market challenges and disappointing trial results for its next-generation treatment CagriSema as key reasons for the leadership change.

This includes the positive phase 3 trial results for the next-generation anti-obesity blockbuster drug CagriSema and the expected first-to-market oral obesity product semaglutide 25 milligrams (mg).

This includes continued solid growth in its blockbuster drug, Keytruda, which saw 6% sales growth YoY to $7.2 billion due to expanded usage in early stage and metastatic cancers. Moreover ...